Main content area

UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers

Cestari, Roberta Natália, Rocha, Adriana, de Oliveira, Renê Donizeti Ribeiro, Lanchote, Vera Lucia
Journal of chromatography 2019 v.1125 pp. 121712
acetonitrile, enzymes, formic acid, gemfibrozil, half life, hyperlipidemia, mass spectrometry, oral administration, pharmacokinetics, ultra-performance liquid chromatography, volunteers
Gemfibrozil (GFZ) is a derivative of fibric acid and is used in the treatment of dyslipidemia. GFZ may affect the metabolism of various drugs, including statins, by inhibiting the sinusoidal influx transporter OATP1B1 and also CYP2C9 and CYP2C8 enzymes. This study presents the development and validation of a rapid, simple, sensitive and reproducible method of GFZ analysis in human plasma using UPLC-MS/MS. The method was applied in a pharmacokinetic study following administration of multiple doses of 600 mg GFZ every 12 h in healthy volunteers (n = 15). GFZ was separated on a C18 column using a mixture of 0.01% formic acid and acetonitrile (40:60, v/v) as the mobile phase at a flow rate of 0.4 mL/min. The method showed linearity in the range from 0.01 μg/mL to 100 μg/mL plasma. The coefficients of variation and the relative standard errors of the accuracy and precision analyses were <15%. The method allowed quantification of plasma concentrations of GFZ in the dose interval of the sixth day of administration of multiple oral doses of GFZ every 12 h. The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72–104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06–8.75) μg/mL, minimum plasma concentration 1.24 (0.87–1.61) μg/mL, maximum plasma concentration 26.73 (21.31–32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42–3.13) h, elimination half-life 2.81 (2.22–3.40) h, apparent total clearance 7.72 (5.85–9.58) L/h, apparent distribution volume 33.97 (18.41–49.53) L. In conclusion, the method for analysis of GFZ in human plasma showed sensitivity, linearity, precision and accuracy compatible with application in pharmacokinetic studies of multiple oral dose of 600 mg GFZ every 12 h.